Abstracts Archive - Page 2560 of 2607 - ACR Meeting Abstracts

Abstract Number: 669 • 2012 ACR/ARHP Annual Meeting
Serum Anti N-Methyl-D-Aspartate Receptor Subunit 1 Antibodies Are Elevated in SLE
Ogawa Eisuke, Nagai Tatsuo, Arinuma Yoshiyuki and Hirohata Shunsei, Rheumatology and infectious diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Previous studies have demonstrated that the presence of autoantibodies against N-methyl-D-aspartate (NMDA) receptor subunit 2 (NR2) is closely associated with brain damages leading to…
Abstract Number: 670 • 2012 ACR/ARHP Annual Meeting
Prolidase Deficiency Induces Antibodies to Sm, Ro60 and Double Stranded DNA
Biji T. Kurien¹, Anil D'souza², Skyler P. Dillon¹, Benjamin F. Bruner³, Timothy Gross⁴, Judith A. James⁵, Ira N. Targoff⁶, Jacen S. Maier-Moore⁷, Isaac T.W. Harley⁸, Heng Wang⁹ and Robert H. Scofield⁷, ¹Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Harding University, Searcy, AR, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁷Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁸Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, ⁹Das Deutsch Center Clinic for Special Needs Children, Middlefield, OH
Background/Purpose: Prolidase is a ubiquitous enzyme found in the cytoplasm. The enzyme specifically cleaves dipeptides containing C-terminal proline or hydroxyproline, in one of the last…
Abstract Number: 631 • 2012 ACR/ARHP Annual Meeting
Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
Simone Fargetti¹, Samuel K. Shinjo², Sandra G. Pasoto¹, Ana L. Calich¹, Eloisa Bonfa³ and Eduardo F. Borba¹, ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that…
Abstract Number: 632 • 2012 ACR/ARHP Annual Meeting
The Effects of Co-Existing Proliferative Histopathology On Membranous Lupus Nephritis
Jennifer L. Graybill¹, Catarina Vila-Inda¹, Chaim Putterman² and Irene Blanco¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) affects up to 60% of SLE patients and is worse in minority communities. Traditionally membranous LN confers a better prognosis than…
Abstract Number: 633 • 2012 ACR/ARHP Annual Meeting
Missed Work Days in Systemic Lupus Erythematosus
Jie Xu¹, Hong Fang² and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Indirect costs are part of the medical and financial burden of SLE. These costs are easy to undervalue because a significant portion of this…
Abstract Number: 634 • 2012 ACR/ARHP Annual Meeting
Adherence to Adult Treatment Panel III Guidelines for Systemic Lupus Patients
Matthew Basiaga and Lisabeth Scalzi, Rheumatology, Penn State Univ/ Hershey, Hershey, PA
Background/Purpose: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) has provided education and guidance for decades on the management of hypercholesterolemia.…
Abstract Number: 635 • 2012 ACR/ARHP Annual Meeting
Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Leslie Harris¹, Ratnesh Chopra¹, Ann K. Rosenthal² and Mary E. Cronin³, ¹Division of Rheumatology/Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus ( SLE) is characterized by the formation of autoantibodies, and over-exuberant antigen presentation may account for some of this pathology .…
Abstract Number: 636 • 2012 ACR/ARHP Annual Meeting
Retrospective Study of Allogenic Mesenchymal Stem Cells Transplantation in Active and Refractory Lupus Nephritis for Induction Therapy
Lingyun Sun, Dandan Wang, Xia Li and Huayong Zhang, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Allogenic mesenchymal stem cells (MSCs) transplantation demonstrated significant clinical efficacy on various autoimmune diseases. Here we retrospectively analyzed the role of allogenic MSCs transplantation…
Abstract Number: 637 • 2012 ACR/ARHP Annual Meeting
Anti-Mullerian Hormone and Ovarian Reserve in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Pak To Chan² and Chi Hung To², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Medicine, Hong Kong, Hong Kong
Background/Purpose: To study the level of anti-mullerian hormone (AMH) and its relationship with age and previous cyclophosphamide (CYC) exposure in patients with systemic lupus erythematosus…
Abstract Number: 638 • 2012 ACR/ARHP Annual Meeting
The Progression of Brain MRI Biomarker of Cognitive Impairment (White Matter Hyperintensity) in Systemic Lupus: A Clinical and Imaging Longitudinal Study
Jamal Mikdashi¹ and Umran Ashruf², ¹Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ²Radiology and Diagnostic Imaging, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: SLE patients are at high risk for accumulation of white matter hyperintensity (WMH) on brain MRI which has been correlated with cognitive impairment. Our…
Abstract Number: 639 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
K. Hobbs¹, D.J. Wallace², V. Strand³, K. Kalunian⁴, B. Kilgallen⁵, S. Bongardt⁶, W.A. Wegener⁷ and D.M. Goldenberg⁷, ¹Denver Arthritis Clinic, Denver, CO, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Brussels, Belgium, ⁷Immunomedics Inc, Morris Plains, NJ
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized, double-blind trials (ALLEVIATE 1 and…
Abstract Number: 640 • 2012 ACR/ARHP Annual Meeting
Association of Body Weight with Cardiovascular Events in Systemic Lupus Erythematosus
George Stojan¹, Homa Timlin², Hong Fang³, Laurence S. Magder⁴ and Michelle Petri³, ¹Division of Rheumatology, Harvard Medical School- Beth Israel Deaconess Medical Center, Boston, MA, ²West Drayton, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Excessive body mass among healthy subjects carries an increased risk of subsequent cardiovascular (CV) events. In healthy subjects, the relationship between body mass index…
Abstract Number: 641 • 2012 ACR/ARHP Annual Meeting
Study of Anti-Müllerian Hormone and Probability of Pregnancy in 112 Systemic Lupus Erythematosus Patients Exposed or Not to Cyclophosphamide
Nathalie Morel¹, Anne Bachelot², Zeina Chakhtoura², Zahir Amoura¹, Olivier Aumaitre³, Jean-Emmanuel Kahn⁴, Du Boutin⁵, Pierre Duhaut⁶, Dominique Farge⁷, Camille Francès¹, Lionel Galicier⁸, Gaëlle Guettrot-Imbert³, Jean-Robert Harlé⁹, Olivier Lambotte¹⁰, Véronique Le Guern¹¹, Jean-Charles Piette¹², Jacques Pourrat¹³, Karim Sacre¹⁴, Damien Sene¹⁵, Salim Trad¹⁶, Elisabeth Vidal¹⁷, Lamiae Grimaldi¹⁸, Christiane Coussieu¹⁹, Nathalie Costedoat-Chalumeau²⁰ and PLUS²¹, ¹Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²Endocrinology, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ³Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁶Internal Medicine and RECIF, CHU Nord, Amiens, France, ⁷Medicine, EBMT, Paris, France, ⁸Internal Medicine, Hopital Saint Louis, Paris, France, ⁹Internal Medicine, CHU Toulouse, Toulouse, France, ¹⁰Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, ¹¹Department of Internal Medicine, Cochin Hospital, Paris, France, ¹²Internal Medicine 2, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ¹³Toulouse University Hospital, University of Toulouse, Toulouse, France, ¹⁴Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ¹⁵Internal Medicine, Hopital Lariboisière, Paris, France, ¹⁶Internal Medicine, Hopital Ambroise Paré, Paris, France, ¹⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹⁸Société Laser, Paris, France, ¹⁹Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²⁰Internal Medicine, Hopital Cochin, Paris, France, ²¹Paris, France
Background/Purpose: Cyclophosphamide (CYC), a drug commonly used in systemic lupus erythematosus (SLE), is associated with a risk of ovarian failure resulting in infertility. In the…
Abstract Number: 642 • 2012 ACR/ARHP Annual Meeting
Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients
Paul R. Dominguez-Gutierrez¹, Angela Ceribelli¹, Minoru Satoh², Eric S. Sobel³, Westley H. Reeves⁴ and Edward K.L. Chan¹, ¹Oral Biology, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Several candidate biomarkers for Systemic Lupus Erythematosus (SLE) have been reported including STAT1, ADAR, CCL2, CXCL10, and miR-146a. This study examines the effects of…
Abstract Number: 643 • 2012 ACR/ARHP Annual Meeting
Clinical Characteristics for Future Development of Systemic Lupus Erythematosus in Korean Patients with Idiopathic Thrombocytopenic Purpura
Yeon-Ah Lee¹, Somi Kim¹, Ran Song² and Sang-Hoon Lee², ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ²Rheumatology, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic inflammatory autoimmune disease capable of exhibiting virtually any clinical symptoms, occasionally presents itself with thrombocytopenic purpura as an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].